secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001140361-25-007862
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences appoints Feng Hsiung to board, stockholders approve 4.3M share increase in equity plan
--------------------------------------------------------------------------------

- Feng Hsiung appointed to board as Class III director effective March 7, 2025; also joins audit committee.
- Stockholders approved Amended 2022 Equity Incentive Plan adding 4,300,000 shares and extending term to 2035.
- Board adopted Amended Inducement Plan reserving extra 500,000 shares for new-hire inducement grants.
- Non-employee director compensation policy revised; each continuing director received 43,900-share option grant.
- CEO Timothy Lu received contingent option for 1,927,073 shares and RSU for 642,358 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/0001140361-25-007862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000114036125007862/ef20045153_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-007862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer